Published in Pituitary on September 01, 2013
Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine (2014) 1.09
Prevalence of colonic polyp and its predictors in patients with acromegaly. Indian J Endocrinol Metab (2016) 0.91
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. Front Endocrinol (Lausanne) (2015) 0.84
The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence (2015) 0.78
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary (2016) 0.78
Medical management of functioning pituitary adenoma: an update. Neurol Med Chir (Tokyo) (2014) 0.77
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One (2014) 0.77
Elevated intraocular pressure in patients with acromegaly. Graefes Arch Clin Exp Ophthalmol (2014) 0.77
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest (2014) 0.76
Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea. BMJ Open (2015) 0.76
Soluble Klotho protein as a novel serum biomarker in patients with acromegaly. Arch Med Sci (2014) 0.75
Acromegaly with cardiomyopathy, cardiac thrombus and hemorrhagic cerebral infarct: a case report of therapeutic dilemma with review of literature. Int J Endocrinol Metab (2015) 0.75
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Front Endocrinol (Lausanne) (2017) 0.75
The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis (2016) 0.75
Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence (2016) 0.75
What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients? J Phys Ther Sci (2015) 0.75
Pituitary adenomas in childhood and adolescence with a focus on intratumoral hemorrhage. Pituitary (2014) 0.75
Preconception counselling for women with acromegaly: More questions than answers. Obstet Med (2015) 0.75
Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening. Pituitary (2014) 0.75
The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord (2017) 0.75
Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy. J Endocrinol Invest (2017) 0.75
High levels of IGF-1 predict difficult intubation of patients with acromegaly. Endocrine (2017) 0.75
[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities]. Internist (Berl) (2017) 0.75
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr Relat Cancer (2017) 0.75
Evidence of dysexecutive syndrome in patients with acromegaly. Pituitary (2017) 0.75
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 6.48
Medical progress: Acromegaly. N Engl J Med (2006) 6.21
Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev (2004) 3.14
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab (1997) 2.35
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science (2006) 2.24
Acromegaly pathogenesis and treatment. J Clin Invest (2009) 2.19
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) (1999) 1.85
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab (2008) 1.79
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol (2005) 1.70
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol (2005) 1.62
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol (1995) 1.53
A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab (2005) 1.51
Mortality in patients with pituitary disease. Endocr Rev (2010) 1.48
Guidelines for acromegaly management. J Clin Endocrinol Metab (2002) 1.48
Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab (1998) 1.48
Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab (2007) 1.47
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab (2008) 1.42
Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) (1994) 1.40
Somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2002) 1.33
Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab (2005) 1.25
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Resistance to somatostatin analogs in acromegaly. Endocr Rev (2010) 1.20
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab (2006) 1.20
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab (2004) 1.18
Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab (2010) 1.17
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) (2003) 1.16
Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab (2004) 1.14
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2005) 1.13
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab (2004) 1.12
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Does acromegaly enhance mortality? Rev Endocr Metab Disord (2008) 1.09
Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med (1992) 1.07
Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut (2002) 1.07
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab (2006) 1.06
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab (2008) 1.05
Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab (2010) 1.05
Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab (2009) 1.04
Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol (2008) 1.04
Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol (2007) 1.02
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol (2001) 1.01
ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab (2009) 1.01
Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab (2007) 1.00
Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab (2007) 0.97
Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) (2001) 0.96
Articular manifestations of acromegaly. Aust N Z J Med (1988) 0.96
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol (2008) 0.95
Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab (2009) 0.95
Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab (2003) 0.95
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) (2007) 0.95
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol (Oxf) (2012) 0.95
Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol (2008) 0.94
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J (2010) 0.93
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest (2008) 0.92
Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol (2006) 0.91
Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) (2007) 0.91
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol (2010) 0.91
A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer (2002) 0.91
Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res (2005) 0.91
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol (2008) 0.90
Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) (2003) 0.90
Diagnosis and treatment of acromegaly complications. J Endocrinol Invest (2003) 0.90
Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol (2010) 0.90
Management of aggressive pituitary adenomas: current treatment strategies. Pituitary (2009) 0.90
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab (2008) 0.89
Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest (2006) 0.89
High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol (2011) 0.89
Gamma knife radiosurgery for pituitary adenomas. J Neurosurg (2000) 0.88
Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) (2005) 0.88
Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol (2000) 0.87
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol (2010) 0.87
Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn (1992) 0.87
The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary (2008) 0.86
Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol (2004) 0.86
Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol (2001) 0.86
Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab (2010) 0.86
A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res (2007) 0.85
Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl (Wien) (1991) 0.84
Clinical implications of growth hormone-secreting tumor subtypes. Endocrine (2012) 0.83
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol (2011) 0.83
The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) (1992) 0.82
Failure of radiotherapy in acromegaly. Eur J Endocrinol (2001) 0.82
High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab (2003) 0.82
Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol (2007) 0.82
Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol (2008) 0.81
Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med (1994) 0.81
Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta (2010) 0.81
Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary (2012) 0.81
Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol (2003) 0.80
No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab (2008) 0.80
[Prognostic factors in the surgical management of acromegaly]. Ann Med Interne (Paris) (1999) 0.80
Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest (1997) 0.79
Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2003) 3.33
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int (2007) 3.12
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med (2000) 2.80
Eating disorders. N Engl J Med (1999) 2.77
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med (1997) 2.66
Synthesis of a cortisol-biotin conjugate and evaluation as a tracer in an immunoassay for salivary cortisol measurement. J Steroid Biochem Mol Biol (1992) 2.56
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab (2000) 2.36
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Effects of KiSS-1 peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat. Endocrinology (2005) 2.23
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet (2000) 2.11
Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet (1997) 2.09
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int (2013) 2.00
Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.95
Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am J Clin Nutr (2001) 1.91
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.91
The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab (1999) 1.89
A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab (1996) 1.85
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol (2007) 1.83
Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol (1997) 1.82
Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology (2005) 1.81
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1999) 1.78
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab (2013) 1.77
Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) (2006) 1.76
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76
A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes (2001) 1.76
High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol (2001) 1.74
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med (2000) 1.74
Turner's syndrome in adulthood. Endocr Rev (2002) 1.72
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
The influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience (2010) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab (1995) 1.68
Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) (2002) 1.68
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol (1999) 1.62
Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab (1989) 1.61
Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab (1999) 1.59
Osteopenia in men with a history of delayed puberty. N Engl J Med (1992) 1.59
Chronic widespread pain is associated with slower cognitive processing speed in middle-aged and older European men. Pain (2010) 1.58
Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab (1998) 1.57
Benefits of Ophdiat, a telemedical network to screen for diabetic retinopathy: a retrospective study in five reference hospital centres. Diabetes Metab (2009) 1.56
Presence of bovine leptin in edible commercial milk and infant formula. J Endocrinol Invest (2002) 1.56
Detection of doping with human growth hormone. Lancet (1999) 1.55
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) (2005) 1.55
Influence of thyroid status on serum immunoreactive leptin levels. J Clin Endocrinol Metab (1997) 1.55
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.54
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology (1995) 1.54
Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr Res (1995) 1.54
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: a prospective study comparing cytologic and histologic findings. Am J Med (1994) 1.54
Decreased bone density in hyperprolactinemic women. N Engl J Med (1980) 1.53
Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) (2000) 1.53
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology (1993) 1.52
Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol (1998) 1.51
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage. J Clin Endocrinol Metab (1997) 1.50
Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. Int J Eat Disord (2000) 1.49
Guidelines for acromegaly management. J Clin Endocrinol Metab (2002) 1.48
Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology (1989) 1.46
Insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 1.45
Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 1.45
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993) 1.44
Presence of leptin in colostrum and/or breast milk from lactating mothers: a potential role in the regulation of neonatal food intake. J Clin Endocrinol Metab (1997) 1.42
Remission of polycythemia vera after surgical cure of acromegaly. Ann Intern Med (1996) 1.41
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med (1991) 1.41
Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) (1997) 1.41
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med (1985) 1.41
Lymphocytic prolactin does not contribute to systemic lupus erythematosus hyperprolactinemia. Clin Exp Rheumatol (2011) 1.41
[Clinically non-functioning hypophyseal adenomas; diagnostic possibilities and therapeutic options]. Ned Tijdschr Geneeskd (1992) 1.40
Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab (1984) 1.39
A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test. Clin Endocrinol (Oxf) (2002) 1.39
The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) (1991) 1.39
Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. Acta Endocrinol (Copenh) (1993) 1.39
Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care (1997) 1.39
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38
Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol (1998) 1.37
[Prolactinoma; diagnosis and treatment]. Ned Tijdschr Geneeskd (1996) 1.37
Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab (1997) 1.36